Delving into the Latest Updates on Dexamethasone/Povidone Iodine with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

PVP-I/dexamethasone, Povidone iodine/dexamethasone

+ [2]

Target

GR

Action

agonists

Mechanism

GR agonists(Glucocorticoid receptor agonists)

Therapeutic Areas

Eye Diseases

Active Indication

Conjunctivitis

Inactive Indication

Adenoviral ConjunctivitisAdenoviridae InfectionsConjunctivitis, Bacterial+ [1]

Originator Organization

CLS Pharma SAS

Active Organization

CLS Pharma SAS

Inactive Organization

Shire Plc

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC6H9I2NO

InChIKeyCPKVUHPKYQGHMW-UHFFFAOYSA-N

CAS Registry25655-41-8

PURPOSETo determine the efficacy of a new formulation of topical dexamethasone 0.1%/povidone-iodine 0.4% (FST-100) in reducing clinical symptoms and infectious viral titers in a rabbit model of adenoviral keratoconjunctivitis.METHODSRabbit corneas were inoculated bilaterally with 2×10(6) plaque-forming-units (PFU) of adenovirus type 5 (Ad5) after corneal scarification. Animals were randomized 1:1:1:1 (five rabbits per group) to FST-100, 0.5% cidofovir, tobramycin/dexamethasone (Tobradex; Alcon Laboratories, Fort Worth, TX) ophthalmic suspension, and balanced salt solution (BSS; Alcon Laboratories). Treatment began 12 hours after viral inoculation and continued for 7 consecutive days. The eyes were clinically scored daily for scleral inflammation (injection), ocular neovascularization, eyelid inflammation (redness), friability of vasculature, inflammatory discharge (pus), and epiphora (excessive tearing). Eye swabs were collected daily before treatment for the duration of the study. Virus was eluted from the swabs and PFU determined by titration on human A549 cells, according to standard procedures.RESULTSThe FST-100 treatment resulted in significantly lower clinical scores (P<0.05) than did the other treatments. The 0.5% cidofovir exhibited the most ocular toxicity compared with FST-100, tobramycin/dexamethasone, and balanced salt solution treatments. FST-100 and 0.5% cidofovir significantly (P<0.05) reduced viral titers compared with tobramycin/dexamethasone or balanced salt solution.CONCLUSIONSFST-100 was the most efficacious in minimizing the clinical symptoms of adenovirus infection in rabbit eyes. FST-100 and 0.5% cidofovir were both equally effective in reducing viral titers and decreasing the duration of viral shedding. By providing symptomatic relief in addition to reducing infectious virus titers, FST-100 should be a valuable addition to treatment of epidemic adenoviral keratoconjunctivitis.

100 Deals associated with Dexamethasone/Povidone Iodine

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Conjunctivitis	Phase 3	-	CLS Pharma SAS	-
Adenoviral Conjunctivitis	Discovery	Austria	Shire Plc	27 Mar 2017
Adenoviral Conjunctivitis	Discovery	Germany	Shire Plc	27 Mar 2017
Adenoviral Conjunctivitis	Discovery	Spain	Shire Plc	27 Mar 2017
Adenoviral Conjunctivitis	Discovery	India	Shire Plc	27 Mar 2017
Adenoviral Conjunctivitis	Discovery	France	Shire Plc	27 Mar 2017
Adenoviral Conjunctivitis	Discovery	Hungary	Shire Plc	27 Mar 2017
Adenoviral Conjunctivitis	Discovery	United Kingdom	Shire Plc	27 Mar 2017
Adenoviral Conjunctivitis	Discovery	Australia	Shire Plc	27 Mar 2017
Adenoviral Conjunctivitis	Discovery	Israel	Shire Plc	27 Mar 2017

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02998554 (CTgov)	Phase 3	Adenoviral Conjunctivitis	156	SHP640 (SHP640)	mlmmgqllnz(dqwjqoxtqr) = wtyjfrmroc zyudoapqha (tnoqxykgfg, ayytthxgar - mxfprzrrfd) View more	-	29 May 2020
				Placebo (Placebo)	mlmmgqllnz(dqwjqoxtqr) = ukiqjhlkht zyudoapqha (tnoqxykgfg, pvziakatzx - aospgdxkrp) View more
NCT02998541 (CTgov)	Phase 3	Adenoviral Conjunctivitis	219	SHP640 (SHP640)	fcgjclaxfu(uglauxvcqm) = levgugkuoj pyyslasocm (kwjrbberzc, bqelqlynlk - zvprlsdhxt) View more	-	27 May 2020
				PVP-I 0.6% (PVP-I 0.6%)	fcgjclaxfu(uglauxvcqm) = hccqyaiymo pyyslasocm (kwjrbberzc, nijwexwupz - vumbelptcc) View more
NCT03004924 (CTgov)	Phase 3	Conjunctivitis, Bacterial	753	SHP640 (SHP640)	ijtbkqahqg(idrcavrxhn) = lfxpyzbbuv cvitkpppkv (sgykaylvir, pmugwilijd - mrtpnihvhe) View more	-	28 Oct 2019
				PVP-I 0.6% (PVP-I 0.6%)	ijtbkqahqg(idrcavrxhn) = knvvttljgu cvitkpppkv (sgykaylvir, hqltiwnsxw - flovflvxwo) View more